Contraindicated (1)bortezomib will raise the stage or effect of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Solid or average CYP2C19 inhibitors might raise mavacamten systemic publicity, causing coronary heart failure due to systolic dysfunction. Screen for hepatitis B virus in all most cancers individuals starting off systemic remedy. Uncover https://carlosf444tfq7.corpfinwiki.com/user